Figure 26: Photograph of Professor Jens Holst with Dr Karen Thorne, a member of his laboratory, carrying out an experiment with a perfused pig pancreas in the 1990s, credit: Holst
GLP-1 agonists are getting a lot of notice lately, mainly due to they help in weight reduction and, in general they also support metabolic health outcomes
Real GLP-1 Medications: Access to semaglutide, tirzepatide, and evidence-based therapies
On social media, most of the microdosing chatter is about small amounts of weight loss, perceived (but not proven!) longevity benefits, and treating many forms of inflammation
Referral to endocrinology or obesity medicine specialists should be considered for complex cases or when treatment goals are not achieved with standard approaches